MUNICH — Adding the investigational factor XIa inhibitor milvexian to standard antiplatelet therapy did not reduce cardiovascular (CV) events after acute coronary syndrome (ACS), despite evidence that the drug was exerting its expected pharmacodynamic effect, according to the phase 3 LIBREXIA ACS trial. The trial was stopped early for futility in November 2025 after a …
Read More
Milvexian Fails to Reduce CV Events After ACS
